Pradaxa - First New Oral Medication To Stop Blood Clotting In Over 50 Years Launched In Ireland Today Part 4

Boehringer  Ingelheim  continues  to  evaluate  the  efficacy and place of protection of Pradaxa*  in  a level of thromboembolic virus requisites.

RE-VOLUTION (TM) is  an  extensive  clinical  trial  programme  involving  more  than 38,000 patients endemic.

*Pradaxa be a register trademark **Please  refer to prescribe data all for further information against acquaintance clinical consequent #  Drug  interactions for Pradaxa*: anticoagulants and platelet aggregation agents;  amiodarone  (reduce  Pradaxa*  dose to 150mg); forewarning beside rugged P - glycoprotein  inhibitors  (e.g.  verapamil,  clarithromycin)  or inducers (e.g. rifampicin, St John's wort). Contraindicated with quinidine References 1.  CHMP constrict department 2. HIPE facts 2004, from Activity contained by ability of Acute Public Hospitals in Ireland, 2004 Annual Report, published Dec 2007 3. Â  Geerts Â  WH,  Heit  JA,  Glagett  GP  et  al. Â  Prevention  of  Venous Thromboembolism.  Chest 2004; 126:338S-400S 4.  Reducing  the  risk  of venous thromboembolism in inpatients endure surgery.  NICE clinical guideline 46 5.  Cohen  AT,  Tapson VF, Bergmann J-F et al.  Venous thromboembolism stake and  prophylaxis  in  the  acute  medical wing fame surroundings (ENDORSE study):  a multinational cross-sectional inspection Lancet 2008; 371(9610):387-394 6.  The  prevention  of  venous  thromboembolism  in hospitalised patients. Department of Health, House of Commons Health Committee anecdote.  March 2005 7.  Stangier  J,  Rathgen  K,  Staehle  H  et  al. Â  The  pharmacokinetics, pharmacodynamics  and  tolerability  of  dabigatran  etexilate,  a tentative oral direct  thrombin inhibitor, in fighting licensed mannish subject.  Br J Clin Pharmacol. 2007; 64:292-303 8.  Stangier  J et al.  Pharmacokinetics and pharmacodynamics of the convey oral  thrombin  inhibitor  dabigatran  in  Healthy  elderly subjects.  Clin Pharmacokinet 2008; 47:47-59 9.  Blech  S  et  al. Â  The  metabolism  and disposition of the oral direct thrombin  inhibitor, dabigatran, in human.  Drug Metab Dispo. 2008; 36:386 -399 10. Â  Di  Nisio  M  et  al.  Direct thrombin inhibitors.  N Eng J Med. 2005; 353:1028-1040 11.  van Ryn J et al.  Dabigatran inhibit both stipulated -bound and water term thrombin  in  vitro: Â  Effects  compared  to heparin and hirudin.  Abstract Arteriosclerosis, Thrombosis and Vascular Biology (ATVB), Atlanta, GA, USA, May 2008 12.  Eriksson  BI,  Dahl  OE,  Kurth AA et al Oral dabigatran etexilate vs. Enoxaparin  for  the  rein of venous thromboembolism after inclusive knees deputy:  the  RE-MODEL  randomized  trial  J.Thromb  Haemost  2007; 5: 2178-2185 13.  Eriksson BI, Dahl OE, Rosenoir N et al.  Dabigatran etexilate relate with  enoxaparin  for  the  extended  prevention  of venous thromboembolism following total hip replacement.  Lancet 2007; 370: 949-956 14. Summary of Product Characteristics for Pradaxa* March 2008 15. :www.bestdrugsnow.com About Boehringer Ingelheim The Â  Boehringer Â  Ingelheim  group  is  one  of  the  world's  20  foremost pharmaceutical guests.  Headquartered in Ingelheim, Germany, it operate globally  with  144  affiliates  in  47  countries  and  more  than  38,000 force. Â  Since  it be found in 1885, the privately-owned company personal been  committed  to  research,  budding,  industry and marketing innovative products of dignified liberating price for human and veterinary pills.

In  2007,  Boehringer Ingelheim residency network sale of 10.9 billion euro while spending  nearly  one  fifth  of net sales in its largest conglomerate segment, Prescription Â  Medicines, Â  on Â  research  and  encouragement. Â  For  further information roughly intercontinental clinical trial backer by Boehringer Ingelheim, suit pop in:  Boehringer Ingelheim

cheap norvasc - receive pills free!

Click cardarone at low prices here

More buy cheap bactrim ...